Research in Experimental Medicine

, Volume 187, Issue 3, pp 175–184 | Cite as

Synthetic arterial grafts cause prolonged increase in the in vivo formation of thromboxane and prostacyclin in humans

  • O. Vesterqvist
  • K. Gréen
  • J. Lewin
  • J. Swedenborg
Original Papers
Received:
Accepted:

Summary

To evaluate the in vivo production of thromboxane A2 and prostacyclin their major urinary metabolites were measured in patients following graft replacement of the abdominal aorta. Specific methods based on gas chromatography-mass spectrometry were used to measure the urinary excretion of 2,3-dinor-TxB2 and 2,3-dinor-6-keto-PGF1α. The excretion of these metabolites increased tenfold and almost fortyfold during post-operative Day 1 and remained elevated 6–10 days p.o. In a group undergoing cholecystectomy smaller changes of shorter duration were seen. It is concluded from this study that synthetic grafts cause prolonged increase in the in vivo formation of thromboxane A2 and prostacyclin. The reason for the increased TxA2 formation is probably platelet interaction with the foreign surface, whereas the increase of PGI2 could be part of a vascular defense against induced thrombotic activity. Those increases may have pathophysiologic implications.

Key words

Thromboxane Prostacyclin Metabolites Synthetic arterial grafts Humans 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Blair JA, Barrow SE, Waddell KA, Lewis PJ, Dollery CT (1982) Prostacyclin is not a circulating hormone in man. Prostaglandins 23:579–589PubMedGoogle Scholar
  2. 2.
    Czervionke RL, Hoak JC, Fry GL (1978) Effect of aspirin on thrombin-induced adherence of platelets to cultured cells from the blood vessel wall. J Clin Invest 62:847–856PubMedGoogle Scholar
  3. 3.
    FitzGerald GA, Pedersen AK, Patrono C (1983) Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67:1174–1177PubMedGoogle Scholar
  4. 4.
    Forder RA, Carey F (1983) Measurements of human venous plasma prostacyclin and metabolites by radioimmunoassay: A reappraisal. Prostaglandins, Leukotrienes Med 12:323–346Google Scholar
  5. 5.
    Goldman M, Simpson D, Hawker RJ, Norcott HC, McCollum CN (1983) Aspirin and dipyridamole reduce platelet deposition on prosthetic femoro-popliteal grafts in man. Ann Surg 198:713–717PubMedGoogle Scholar
  6. 6.
    Gréen K, Vesterqvist O (1986) In vivo synthesis of thromboxane and prostacyclin in man in health and disease. Data from GC-MS measurements of major urinary metabolites. Adv Prostaglandin, Thromboxane Leukotriene Res 16:309–324Google Scholar
  7. 7.
    Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2994–2998PubMedGoogle Scholar
  8. 8.
    Hutton RA, Chow FPR (1982) Radioimmunoassay of 6-keto-PGF1α in plasma: An artefact introduced by plasma extraction. Br J Haematol 51:327Google Scholar
  9. 9.
    Huval WV, Lelcuk S, Allen PD, Mannick JA, Shepro D, Hectman HB (1984) Determinants of cardiovascular stability during abdominal aortic aneurysmectomy (AAA). Ann Surg 199:216–222PubMedGoogle Scholar
  10. 10.
    Johnson RA, Morton DR, Kinner JH, Gorman RR, McGuire JC, Sun FF, Whittaker N, Bunting S, Salmon J, Moncada S, Vane JR (1976) The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 12:915–928PubMedGoogle Scholar
  11. 11.
    McCollum CN, Goldman M (1985) Platelet-inhibitory therapy in reconstructive arterial surgery. In: Neri Serneri GA, McGiff JC, Paoletti R, Born GVR (eds) Adv Prostaglandin, Thromboxane Leukotriene Res, vol 13. Raven Press, New York, pp 301–309Google Scholar
  12. 12.
    Moncada S, Gryglewski R, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663–665PubMedGoogle Scholar
  13. 13.
    Norcott HC, Goldman M, Hawker RJ, Rafiqi EI, Drolc Z, McCollum CN (1982) Platelet inhibitory drugs: An in vivo method of evaluation in patients. Thromb Haemostas 48:307–310Google Scholar
  14. 14.
    Oblath RW, Buckley FO, Green RM, Schwartz SI, DeWeese JA (1978) Prevention of platelet aggregation and adherence to prosthetic vascular grafts by aspirin and dipyridamole. Surgery 84:37–43PubMedGoogle Scholar
  15. 15.
    Pumphrey CW, Chesebro JH, Dewanjee MK, Wahner HW, Hollier LH, Pairolero PC, Fuster V (1983) In vivo quantitation of platelet deposition on human peripheral arterial bypass grafts using Indium-111-labelled platelets. Am J Cardiol 51:796–801PubMedGoogle Scholar
  16. 16.
    Ritchie JL, Stratton JR, Thiele B, Hamilton GW, Warrick LN, Huang TW, Harker LA (1981) Indium-111-platelet imaging for detection of platelet deposition in abdominal aneurysms and prosthetic arterial grafts. Am J Cardiol 47:882–889PubMedGoogle Scholar
  17. 17.
    Roberts LJ, Sweetman BJ, Oates JA (1981) Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem 256:8384–8393PubMedGoogle Scholar
  18. 18.
    Rosenkrantz B, Fischer C, Weimer KE, Frölich JC (1980) Metabolism of prostacyclin and 6-keto-prostaglandin F1α in man. J Biol Chem 255:10194–10198PubMedGoogle Scholar
  19. 19.
    Rosenkranz B, Frölich JC (1984) Problems of assessment of prostacyclin formation in vivo. Prostaglandins 27:655–657PubMedGoogle Scholar
  20. 20.
    Utsunomiya T, Krausz MM, Dunham B, Mannick JA, Allen PD, Shepro D, Hechtman HB (1981) Maintenance of cardiodynamics with aspirin during abdominal aortic aneurysmectomy (AAA). Ann Surg 194:602–608PubMedGoogle Scholar
  21. 21.
    Vesterqvist O, Gréen K, Lincoln FH, Sebek OK (1983) Development of a GC-MS method for quantitation of 2,3-dinor-TxB2 and determinations of the daily urinary excretion rates in healthy humans. Thromb Res 33:39–49Google Scholar
  22. 22.
    Vesterqvist O, Gréen K (1984) Development of a GC-MS method for quantitation of 2,3-dinor-6-keto-PGF1α and determination of the urinary excretion rates in healthy humans under normal conditions and following drugs. Prostaglandins 28:139–154PubMedGoogle Scholar
  23. 23.
    Vesterqvist O, Gréen K (1984) Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions. Prostaglandins 27:627–644PubMedGoogle Scholar
  24. 24.
    Vesterqvist O (1986) Rapid recovery of in vivo prostacyclin formation after inhibition by aspirin. Evidence from measurements of the major urinary metabolite of prostacyclin by GC-MS. Eur J Clin Pharmacol 30:69–73PubMedGoogle Scholar
  25. 25.
    Winter M, Frampton G, Bennet A, Cameron JS, Trompeter RS, Carey F, Forder RA, Greaves M, Preston FE (1982) Prostacyclin and thromboxane A. Correspondence. Br Med J 284:418–421Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • O. Vesterqvist
    • 1
  • K. Gréen
    • 1
  • J. Lewin
    • 2
  • J. Swedenborg
    • 2
  1. 1.Dept. of Clinical ChemistryKarolinska HospitalStockholmSweden
  2. 2.Dept. of SurgeryKarolinska HospitalStockholmSweden

Personalised recommendations